Repurposing regulatory agency-approved molecules, with proven safety in humans, is an attractive option for developing new treatments for disease. We identified and assessed the efficacy of 3 drugs predicted by an screen as having the potential to treat -DOPA-induced dyskinesia (LID) in Parkinson's disease.

中文翻译：

---

使用人工智能识别重新利用药物来治疗左旋多巴引起的运动障碍


重新利用监管机构批准的、在人体中已被证明安全的分子，是开发新的疾病治疗方法的一个有吸引力的选择。我们鉴定并评估了 3 种通过筛选预测有可能治疗帕金森病中由 β-多巴引起的运动障碍 (LID) 的药物的疗效。